Bendamustine and Rituximab in Treating Patients With Previously Untreated or Relapsed Chronic Lymphocytic Leukemia
Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
CLL2M is a phase 2, multicenter, open label study to investigate the possible therapeutic
benefits of using bendamustine in combination with rituximab for the treatment of patients
with previously untreated or relapsed CLL.